This variant was first discovered in South Africa in October and has now been found in more than a dozen countries.
In both studies, this work was done in the laboratory, not in the personnel, so more research is needed to assess the real threat of the new variant.
Alex Sigal, a virologist at the African Ministry of Health, said: “I think there is evidence that these mutations-and other mutations-will appear on a global scale-and are already emerging-from previous infections. Escaping antibodies in the middle.” The Institute and the Max Planck Institute of Infection Biology told CNN. “This is worrying.”
It is not clear whether this means that if someone already has Covid-19, whether they will be vulnerable to the new variant, or what this means for people who have already been vaccinated.
Jesse Bloom, a virologist at the Fred Hutchinson Cancer Research Center, said: “It’s good to see two groups independently come up with the same basic answer.
Compared with the South African study, the study observed far fewer variant mutations.
None of the studies have been peer reviewed or published in medical journals.
Although scientists are studying whether these variants are particularly dangerous-and multiple laboratories around the world are conducting research-one thing is clear: If you can, please buy a vaccine.
Siegel said, “If I could, I would definitely get it.” “My father-in-law had the opportunity to fly to Israel and get it, but I drove him out of home because you can’t bring it here in South Africa. ”
In his research, Sigal found that the antibodies from all six subjects were unable to completely resist the new mutation.
He said: “One participant responded well, but no one was unscathed.”
The research results have been published on the KRISP website, the KwaZulu-Natal Research Innovation and Sequencing Platform. Two other studies were posted on the pre-print server.
In a study with similar findings, blood came from 44 Covid-19 patients in South Africa. Almost all of their cases were confirmed to have occurred before September, which is before the variant was discovered in South Africa.
Then, the researchers began to study whether their antibodies would resist the new variants.
For about half of the 44 people, their antibodies cannot resist the new variant. For the other half, the antibody response was weakened, but not completely eliminated.
In the third study conducted by Rockefeller University, researchers examined the blood of 20 people who had received the Moderna or Pfizer vaccine. Different mutations in the virus do allow certain types of antibodies to escape, but the volunteers’ immune system throws a lot of different types of antibodies at the virus.
The Rockefeller University study found fewer mutations than the two studies in South Africa. It looked at three key mutations on the spikes on top of the coronavirus because these are part of the virus that the vaccine targets.
John Moore, a vaccine researcher at Will Cornell Medical Corporation, said: “That’s useful, but it’s not all.”
However, the South African study used the virus itself or its model, which contains eight spike mutations.